Company · Public · LCTX
Lineage Cell Therapeutics, Inc.
Clinical-stage company manufacturing allogeneic cell transplants intended to replace cells lost to age-related degeneration, led by a retinal pigment epithelium programme in dry age-related macular degeneration.
Listing
Public
Ticker
LCTX
Headquarters
Carlsbad, US
Founded
1990
Technology
Allogeneic cell transplant therapies from pluripotent lines
Category
Longevity thesis
Where age-related disease is driven by cell loss, transplanting manufactured replacement cells is a more direct route than modifying the surviving tissue.
Programmes
- OpRegen (RG6501)Phase 2a
Geographic atrophy in dry age-related macular degeneration
- OPC1Phase 1/2a
Spinal cord injury
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.